Emerging targeted strategies in advanced hepatocellular carcinoma

Seminars in Liver Disease

Volumn 33, Issue SUPPL.1, 2013, Pages

  Finn, Richards ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

angiogenesis inhibition; brivanib; combination therapy; hepatocellular carcinoma; mTOR inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE DEIMINASE; BEVACIZUMAB; BRIVANIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; LINIFANIB; ORANTINIB; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TIVANTINIB;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DRUG TARGETING; HUMAN; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84874397688     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0033-1333632     Document Type: Article

References (83)

1. Schütte K., Bornschein J., Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis: 2009; 27 2 80 92
2. Imamura H., Matsuyama Y., Tanaka E., et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol: 2003; 38 2 200 207 (Pubitemid 36169630)
3. Shirabe K., Kanematsu T., Matsumata T., Adachi E., Akazawa K., Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology: 1991; 14 5 802 805
4. Poon R. T., Fan S. T., Lo C. M., Liu C-L, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg: 1999; 229 2 216 222 (Pubitemid 30191795)
5. Llovet J. M., Bruix J. for the Barcelona-Clinic Liver Cancer Group Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology: 2003; 37 2 429 442 (Pubitemid 36152543)
6. Marin J. JG, Castaño B., Martinez-Becerra P., Rosales R., Monte M. J. Chemotherapy in the treatment of primary liver tumours. Cancer Ther: 2008; 6 711 728
7. Llovet J. M., Ricci S., Mazzaferro V., et al. SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med: 2008; 359 4 378 390
8. Cheng A. L., Kang Y. K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol: 2009; 10 1 25 34
9. Sanz-Cameno P., Trapero-Marugán M., Chaparro M., Jones E. A., Moreno-Otero R. Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol: 2010; 2010 272170
10. Semela D., Dufour J-F. Angiogenesis and hepatocellular carcinoma. J Hepatol: 2004; 41 5 864 880 (Pubitemid 39434320)
11. Park Y. N., Kim Y-B, Yang K. M., Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med: 2000; 124 7 1061 1065 (Pubitemid 30602050)
12. Poon R. T., Ng I-O, Lau C., et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg: 2001; 233 2 227 235 (Pubitemid 32106077)
13. Poon R. T., Lau C., Pang R., Ng K. K., Yuen J., Fan S. T. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol: 2007; 14 6 1835 1845 (Pubitemid 46870942)
14. Mas V. R., Maluf D. G., Archer K. J., Yanek K. C., Fisher R. A. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation: 2007; 84 10 1262 1271 (Pubitemid 351339314)
15. Poon R. T., Ho J. W., Tong C. S., Lau C., Ng I. O., Fan S. T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg: 2004; 91 10 1354 1360 (Pubitemid 39331462)
16. Poon R. T., Lau C., Yu W. C., Fan S. T., Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep: 2004; 11 5 1077 1084
17. Hsu P. I., Chow N. H., Lai K. H., et al. Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res: 1997; 17 4A 2803 2809
18. Basilico C., Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res: 1992; 59 115 165
19. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev: 2005; 16 2 159 178 (Pubitemid 40616114)
20. Uematsu S., Higashi T., Nouso K., et al. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol: 2005; 20 4 583 588 (Pubitemid 40755271)
21. Poon R. T., Ng I. O., Lau C., Yu W. C., Fan S. T., Wong J. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg: 2001; 182 3 298 304 (Pubitemid 32918381)
22. Yoshiji H., Kuriyama S., Yoshii J., et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology: 2002; 35 4 834 842 (Pubitemid 34258377)
23. Huang X., Yu C., Jin C., et al. Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis. Cancer Res: 2006; 66 3 1481 1490 (Pubitemid 43259929)
24. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer: 2008; 8 8 592 603
25. Sawey E. T., Chanrion M., Cai C., et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell: 2011; 19 3 347 358
26. Kudo M. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig Dis: 2011; 29 3 289 302
27. Bjornsti M. A., Houghton P. J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer: 2004; 4 5 335 348 (Pubitemid 38579480)
28. Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther: 2009; 9 2 247 261
29. Llovet J. M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology: 2008; 14 1312 1327
30. Villanueva A., Chiang D. Y., Newell P., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology: 2008; 135 6 1972 1983, e1-e11
31. Schmitz K. J., Wohlschlaeger J., Lang H., et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol: 2008; 48 1 83 90 (Pubitemid 350191996)
32. Abou-Alfa G. K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol: 2006; 24 26 4293 4300 (Pubitemid 46630787)
33. Finn R. S. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res: 2010; 16 2 390 397
34. Boyault S., Rickman D. S., de Reyniès A., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology: 2007; 45 1 42 52 (Pubitemid 46144363)
35. Rimassa L., Porta C., Borbath I., et al. Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase II trial (RCT). J Clin Oncol: 2012; 30 (Suppl): Abstract 4006
36. Ito Y., Takeda T., Sakon M., et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer: 2001; 84 10 1377 1383 (Pubitemid 32522107)
37. Wu J., Zhu A. X. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol: 2011; 4 30 41
38. Siegel A. B., Zhu A. X. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer: 2009; 115 24 5651 5661
39. Siegel A. B., Olsen S. K., Magun A., Brown R. S. Jr. Sorafenib: where do we go from here? Hepatology: 2010; 52 1 360 369
40. Zhu A. X., Sahani D. V., Duda D. G., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol: 2009; 27 18 3027 3035
41. Cheng A., Kang Y., Lin D., et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol: 2011; 29 (suppl): Abstract 4000
42. Park J. W., Finn R. S., Kim J. S., et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res: 2011; 17 7 1973 1983
43. Llovet J. M., Decaens T., Raoul J-L., et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study. Abstract presented at: 47th Annual Meeting of the European Association for the Study of the Liver; April 18-22, 2012; Barcelona, Spain
44. Toh H-C, Chen P-J, Carr B. I., et al. Linifanib in advanced hepatocellular carcinoma (HCC): a phase 2 trial. Hepatology: 2010; 52 01 Abstract 1777
45. Philip P. A., Mahoney M. R., Allmer C., et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol: 2005; 23 27 6657 6663 (Pubitemid 46190260)
46. Thomas M. B., Chadha R., Glover K., et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer: 2007; 110 5 1059 1067 (Pubitemid 47312872)
47. Zhu A. X., Rosmorduc O., Evans J., et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Ann Oncol: 2012; 23 09 Abstract LBA2
48. Siegel A. B., Cohen E. I., Ocean A., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol: 2008; 26 18 2992 2998
49. Zhu A. X., Finn R. S., Mulcahy M. F., et al. A phase II study of ramucirumab as first-line monotherapy in patients with advanced hepatocellular carcinoma. J Clin Oncol: 2010; 28 15S Abstract 4083
50. Zhu A. X., Abrams T. A., Miksad R., et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer: 2011; 117 22 5094 5102
51. Glazer E. S., Piccirillo M., Albino V., et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol: 2010; 28 13 2220 2226
52. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). Available at: http://clinicaltrials.gov/ct2/show/NCT01015833. Accessed January 11, 2012
53. Sorafenib in the first-line treatment of advanced hepatocellular carcinoma with Child-Pugh liver function class B: multicentre phase 3 randomized trial. Available at: http://clinicaltrials.gov/cts/show/NCT01405573. Accessed January 11, 2012
54. An open-label, randomized phase 3 study of the efficacy and tolerability of linifanib (ABT-869) versus sorafenib in subjects with advanced hepatocellular carcinoma (HCC). Available at: http://clinicaltrials.gov/ct2/show/NCT01009593. Accessed January 11, 2012
55. A randomized, double-blind multicenter phase III study of brivanib versus sorafenib as first-line treatment in patients with hepatocellular carcinoma (BRISK-FL). Available at: http://clinicaltrials.gov/ct2/show/NCT00858871. Accessed January 11, 2012
56. BRISK-FL study with investigational compound brivanib in hepatocellular carcinoma does not meet overall survival primary endpoint [press release]. Princeton, NJ: Bristol-Myers Squibb; July 19, 2012. Available at: http://www.reuters.com/article/2012/07/19/idUS218420+19-Jul-2012+BW20120719. Accessed July 20, 2012
57. A randomized, double-blind, multi-center phase III study of brivanib plus best supportive care (BSC) versus placebo plus BSC in Asian subjects with advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to sorafenib (BRISK-APS). Available at: http://clinicaltrials.gov/ct2/show/ NCT01108705. Accessed January 11, 2012
58. A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced hepatocellular carcinoma after failure of sorafenib treatment-The EVOLVE-1 Study. Available at: http://clinicaltrials.gov/ct2/show/ NCT01035229. Accessed January 11, 2012
59. A multicenter, randomized, double-blind, phase 3 study of ramucirumab (IMC-1121B) drug product and best supportive care (BSC) versus placebo and BSC as second-line treatment in patients with hepatocellular carcinoma following first-line therapy with sorafenib (REACH). Available at: http://clinicaltrials. gov/ct2/show/NCT01140347. Accessed January 11, 2012
60. A DI-PEG 20 versus placebo in subjects with advanced hepatocellular carcinoma who have failed prior systemic therapy. Available at: http://clinicaltrials.gov/ct2/show/NCT01287585. Accessed September 25, 2012
61. A phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation. Available at: http://clinicaltrials.gov/ct2/show/ NCT00692770. Accessed February 23, 2012
62. A phase III randomized, double-blind trial of chemoembolization with or without sorafenib in unresectable hepatocellular carcinoma (HCC) in patients with and without vascular invasion. Available at: http://clinicaltrials.gov/ct2/ show/NCT01004978. Accessed February 23, 2012
63. TACE-2 A randomized placebo-controlled, double blinded, phase III trial of sorafenib in combination with transarterial chemoembolization in hepatocellular cancer. Available at: http://clinicaltrials.gov/ct2/show/ NCT01324076. Accessed February 23, 2012
64. A randomized, double-blind, multicenter phase III study of brivanib versus placebo as adjuvant therapy to trans-arterial chemo-embolization (TACE) in patients with unresectable hepatocellular carcinoma (The BRISK TA Study). Available at: http://clinicaltrials.gov/ct2/show/NCT00908752. Accessed January 11, 2012
65. Orantinib in combination with transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma (ORIENTAL). Available at: http://clinicaltrials.gov/ct2/show/NCT01465464. Accessed September 25, 2012
66. Faivre S., Raymond E., Boucher E., et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol: 2009; 10 8 794 800
67. Huynh H., Ngo V. C., Fargnoli J., et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res: 2008; 14 19 6146 6153
68. Finn R. S., Kang Y. K., Mulcahy M., et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res: 2012; 18 7 2090 2098
69. Albert D. H., Tapang P., Magoc T. J., et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther: 2006; 5 4 995 1006 (Pubitemid 43724600)
70. Blaszkowsky L., Abrams T., Miksad R., et al. Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma. J Clin Oncol: 2010; 28 (Suppl): Abstract e14542
71. Thomas M. B., Morris J. S., Chadha R., et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol: 2009; 27 6 843 850
72. Finn R. S., Poon T. P., Yau T., et al. Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol: 2011; 29 (Suppl): Abstract 4074
73. Abou-Alfa G. K., Johnson P., Knox J. J., et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA: 2010; 304 19 2154 2160
74. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). Available at: http://clinicaltrials.gov/ct2/show/NCT01015833. Accessed January 11, 2012
75. Hsu C-H, Yang T-S, Hsu C., et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer: 2010; 102 6 981 986
76. Sun W., Sohal D., Haller D. G., et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer: 2011; 117 14 3187 3192
77. Zhu A. X., Blaszkowsky L. S., Ryan D. P., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol: 2006; 24 12 1898 1903 (Pubitemid 46638989)
78. Carmeliet P., Jain R. K. Angiogenesis in cancer and other diseases. Nature: 2000; 407 6801 249 257
79. Li X., Feng G-S, Zheng C-S, Zhuo C-K, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol: 2004; 10 19 2878 2882 (Pubitemid 39303010)
80. Sergio A., Cristofori C., Cardin R., et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol: 2008; 103 4 914 921 (Pubitemid 351506379)
81. Pawlik T. M., Reyes D. K., Cosgrove D., Kamel I. R., Bhagat N., Geschwind J. F. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol: 2011; 29 30 3960 3967
82. Lencioni R., Zou J. M., Leberre M., et al. Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma: Phase II, randomized, double-blind SPACE trial. J Clin Oncol: 2012; 30 04 Abstract LBA154
83. Okita K., Imanaka K., Chida N., et al. Phase III study of sorafenib in patients in Japan and Korea with advanced hepatocellular carcinoma (HCC) treated after transarterial chemoembolization (TACE). Abstract presented at the 2010 Gastrointestinal Cancers Symposium; January 22-24, 2010; Orlando, FL